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Inflammatory Markers as Predictors in Primary Liver Cancers with Emphasis on 
Chronic Viral Hepatitis 
 
Cortlandt M. Sellers and Hyun S. Kim.  Section of Interventional Radiology, Department 
of Radiology and Biomedical Imaging, Yale University, Yale School of Medicine, New 
Haven, CT, USA. 
 
Inflammation and the immune system significantly impact the development, progression, 
and treatment response of primary liver cancers (PLC), namely hepatocellular carcinoma 
(HCC) and intrahepatic cholangiocarcinoma (ICC). This retrospective study investigated 
the peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio 
(PLR), and systemic immune-inflammatory index (SII) as  prognostic biomarkers in 
patients with PLC in the setting of advanced liver disease and chronic viral hepatitis. 
Patients diagnosed with HCC or ICC from 2005 to 2016 were selected from the cancer 
registry of a single tertiary care institution. Baseline NLR was calculated within 30 days 
prior to treatment and was dichotomized at the median. Kaplan-Meier overall survival 
(OS) curves and Cox hazard proportional models were performed. Tumor and liver 
reserve parameters were included and analyzed in multivariable analyses (MVA). 581 
HCC patients and 109 ICC patients met inclusion criteria. In both forms of PLC, the low-
NLR group demonstrated higher median overall survival vs. the high-NLR group 
(p<0.01). Log-transformed NLR was also associated with decreased OS, after 
multivariable adjustment for confounders (p<0.05). In HCC, viral hepatitis was identified 
as a NLR effect modifier (interaction term p<0.05) on MVA. In ICC, advanced liver 
disease acted as an effect modifier for the NLR (p<0.05). Lower baseline neutrophil-to-
lymphocyte ratio is associated with increased overall survival in HCC and ICC and has 
more utility than the PLR or the SII as a prognostic marker. The impact of the NLR is 
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Primary liver cancer (PLC) is the seventh most common cancer worldwide (1), the third 
most common cause of cancer death (2), and carries a poor prognosis (1, 3, 4).  
Hepatocellular carcinoma (HCC) comprises 70-85% of primary liver cancer cases, while 
intrahepatic cholangiocarcinoma (ICC) makes up approximately 5-10% (5).  In the 
United States (U.S.), HCC incidence (6 per 100,000 in 2010) (6) is increasing, and it is 
one of the fastest-growing solid tumor malignancies (7, 8).  In East Asia the incidence of 
HCC is nearly six times that number (35.5 per 100,000), possibly due to high endemic 
rates of hepatitis B viral infection (HBV) (9).  It is speculated that up to 50% of 
hepatocellular carcinoma cases worldwide are HBV-related (10, 11); however, in the 
U.S., over a third of HCC cases are associated with hepatitis C virus (HCV) (12).  Other 
common risk factors for HCC include chronic alcohol consumption, non-alcoholic 
steatohepatitis (NASH), and exposure to aflatoxin (13).  In recent years in the United 
States, the incidence of NASH-related hepatocellular carcinoma has increased (14, 15, 
16).  
 
Currently, transplant and resection are the only potentially curative therapies available for 
HCC.  Locoregional therapies (LRT) such as transarterial chemoembolization (TACE), 
thermal ablation, and yittrium-90 radioembolization (Y-90) may be used to treat 
inoperable disease and as a bridging therapy in patients awaiting transplant (see Fig. 1, 
Fig. 2).  Locoregional therapies induce tumor cell death and necrosis through radiation, 
physical destruction, or elimination of vascular supply in combination with chemotherapy 





taken up by antigen-presenting cells and which then induce a tumor-specific immune 
response (18).  Ablation in particular has been shown to promote dendritic cell 
maturation, resulting in increased T-cell stimulatory properties (19, 20).  This release of 
tumor antigens may increase the effectiveness of LRT beyond eradication of visible 
lesions.  
 
Fig. 1. Drug-eluting bead-TACE in HCC.  A 94-year-old patient with NASH developed a 
solitary HCC as seen on MRI (a) and angiography (b). c) Pot-treatment cone beam CT 
confirmed drug-eluting bead deposition within the tumor. d) Three-month post-treatment 
follow-up MRI demonstrated complete response. Images taken from Dendy et al (21) and 








Fig. 2. Two cases of infiltrative HCC with portal vein thrombosis following treatment 
with a single high-dose Yittrium90-radioembolization. Case 1 slides (A) with 
Hematoxylin-eosin stain demonstrates complete pathologic necrosis (arrowhead) of the 
tumor bed with glass beads in the necrotic parenchyma (arrow) and a partially 
recanalized segmental portal vein (star). Case 2 slides (B) Hematoxylin-eosin stain 
demonstrates atrophic fibrotic parenchyma (arrowhead) with complete pathologic 
necrosis of the tumor bed with glass beads (arrow). Figures taken from Dendy (2017) 
(22) and used with permission of authors. 
 
Intrahepatic cholangiocarcinoma (ICC) has an annual age-standardized incidence rate in 
Western countries of <1.5 cases per 100,000 persons (23). A recent review of ICC cases 
in the National Cancer Database (NCDB) by Uhlig et al (24) found an increase in the 
annual number new of ICC cases from 2004 to 2015 (see Fig. 3).  Among intrahepatic 
cholangiocarcinomas, there are multiple distinct gross morphologies, namely mass-
forming ICC, periductal infiltrating ICC and intraductal growth ICC (25).  Major risk 
factors for ICC include primary sclerosing cholangitis, intrahepatic lithiasis, congenital 
anomalies of the biliary tree, liver fluke infection, chronic liver disease and cirrhosis, and 
less common risk factors include toxic exposure to chemicals such as thorotrast (26).  In 
addition, it is thought that exposure to viral hepatitis (27), non-alcoholic fatty liver 






Fig. 3. Annual number of ICC cases contained in the NCDB database demonstrating 
increasing proportion of non-surgical management and decreased proportion of no-
treatment. Figure used with permission from Uhlig et al (24). 
 
Intrahepatic cholangiocarcinoma carries a dismal prognosis, with three- and five-year 
survival rates of 30% and 18% (29).  As few as 15% of patients may present with 
resectable disease (30).  For patients who are diagnosed at an earlier stage, surgical 
resection is recommended whenever possible (31).  Unfortunately, up to 36% of surgical 
candidates may be found to have unresectable disease on staging diagnostic laparoscopy 
(32).  The first line of therapy for patients with inoperable ICC consists of systemic 
chemotherapy, with a combination of gemcitabine and cisplatin being the standard of 
care (31).  Recently, locoregional therapies have been used in ICC for palliation (33, 34) 
and as an adjuvant therapy alongside systemic chemotherapy (35) or resection (36), with 





38, 39). An example of the use of radiofrequency ablation (RFA) in a 62-yr-old male 
with ICC is shown in Fig. 4. 
 
a)  b)   
c)  
Fig. 4. RFA in ICC. A 62-year-old male with a solitary ICC lesion as seen on ultrasound 
(a) and MRI (b). c) Post-treatment MRI one month later demonstrates the ablation cavity 
(arrow) with no evidence of cancer recurrence. 
  
Chronic inflammation and the immune response are integral to the development of 
cancers, including those that arise in the liver (40, 41).  It is hypothesized that the risk 
factors associated with HCC and ICC create a neoplasia-prone environment through liver 
injury and subsequent activation of the immune response, leading to the generation of 
free radicals as well as the stimulation of cytokines, chemokines, and other growth 





DNA synthesis, may cause a higher rate of cellular mutations and accelerate 
advancement along the cancer pathway (42). 
 
A growing body of work indicates that inflammation and the immune response play key 
roles in the development and progression of hepatocellular carcinoma specifically.  
Increased levels of tumor infiltrating CD8+ T-cells have been associated with improved 
survival in HCC (43), while increased numbers of regulatory T-cells have been 
associated with decreased immune response to the tumor, poorer prognosis, and increased 
risk of metastasis (44, 45).  Immune biomarkers that have been considered prognostic 
markers for HCC include the neutrophil-to-lymphocyte ratio (NLR), platelet-to-
lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), programmed-death-
1 (PD-1) receptor, programmed death-ligand 1 (PD-L1), and C-X-C motif chemokine 12 
(CXCL12) (43, 46).   
 
The neutrophil-to-lymphocyte ratio was first defined in a cohort of intensive care 
oncologic patients, where the severity of their clinical course was found to correspond 
with the degree of neutrophilia and lymphocytopenia (47).  The NLR is thought to 
describe a “narrow relation between innate and adaptive cellular immune responses in 
health and diseases” (48) and may be useful in determining the presence of subclinical 
inflammation.  Since that first study, the NLR has been evaluated as a prognostic marker 
in multiple solid organ cancers, including hepatocellular carcinoma, breast, renal cell 
carcinoma, melanoma, lung, and head and neck cancer (49, 50, 51, 52, 53, 54), in 





hospitalization in patients with hepatic cirrhosis (55).  Alongside HCC (56, 57), the 
platelet-to-lymphocyte ratio has been studied in breast (58), gastric (59), and non-small 
cell lung cancer (60) and the systemic immune-inflammatory index has been examined in 
urothelial carcinoma (61). 
 
Despite increasing interest in the NLR and other immune biomarkers in HCC and ICC 
(62, 63, 64, 65), few have examined the relevance of these biomarkers in a Western 
population. Further, previous research on NLR has focused on populations with high 
rates of hepatitis B infection, while hepatitis C tends to be more prevalent in the U.S.  It 
is also unclear which, if any, of the three inflammatory markers NLR, PLR, and SII is 
most effective as a prognostic marker.   
 
Statement of Purpose: The aim of this work was to investigate the relevance of the 
NLR, PLR, and SII as prognostic biomarkers in patients with primary liver cancers, with 
an emphasis on patients with chronic viral hepatitis and chronic liver disease, and the a 
priori hypothesis that the chronic inflammation associated with liver disease and/or viral 




This study protocol was in compliance with the ethical guidelines set forth by the 1975 
Declaration of Helsinki as well as the Health Insurance Portability and Accountability 





commencement of the study. We retrospectively analyzed adult patients from the Yale 
Cancer Center registry diagnosed with HCC or ICC based on histopathological and/or 
radiological assessment according to guidelines from the National Cancer Institute and 
American Association for the Study of Liver Diseases between 2005 and 2016 and who 
received treatments through the hospital system. A flow-chart depicting study design can 
be found in Fig. 5. 
 
Treatment allocation was selected by a multi-disciplinary tumor board.  For the purposes 
of this study, treatment was stratified into systemic therapy, locoregional therapy (LRT), 
resection, and transplantation.  Systemic therapy consisted of patients who received 
chemotherapy with or without radiation oncology treatment.  In hepatocellular carcinoma 
patients, locoregional therapy was then substratified into transarterial 
chemoembolization, ablation, and combined locoregional therapy (combo LRT).  HCC 
patients who received both transarterial chemoembolization and ablation within a two-
month period were classified as combo LRT, and patients who received systemic therapy 
as well as either transarterial chemoembolization or ablation were classified as 
transarterial chemoembolization and ablation, respectively.  Patients who received 
resection or transplant following locoregional therapy were classified as resection and 
transplant, respectively.  HCC patients who received solely radiation oncology therapy 
were excluded due to small sample size (n=8). 
 
For patients with intrahepatic cholangiocarcinoma, treatment allocation was first 





therapies (including transarterial chemoembolization or TACE and Yittrium-90 
radioembolization), ablation, and resection.  Catheter-directed therapies and ablation 
were then combined into locoregional therapies (LRT).  Patients who received LRT or 
resection following or in conjunction with systemic therapy were classified as LRT and 
resection, respectively. “Non-surgical treatment” consisted of locoregional therapies and 
systemic therapies.   
 
Exclusion criteria included individuals under the age of 18, patients with incomplete 
treatment or follow-up data, and patients receiving palliative therapy.  Patients with a 
proven pathologic diagnosis of combined HCC and cholangiocarcinoma were also 

























Fig. 5. Flow-charts demonstrating study design. a) for HCC cohort. b) for ICC cohort. 
 
Data Acquisition 
Variables reported in the cancer registry included age at diagnosis, gender, ethnicity, 
American Joint Committee on Cancer (AJCC) staging, treatment status, and survival 
data.  Further data was acquired through electronic medical record review, which 
explicitly identified therapy status and the temporal sequence of treatments.  Additional 
chart review for ascites and hepatic encephalopathy data was performed.  Along with this 
data, baseline laboratory values were used to calculate Child-Pugh and Model for End-
Stage Liver Disease (MELD) scores.  Baseline tumor burden, liver disease, and 
performance status were used to calculate Barcelona Clinic Liver Cancer (BCLC) staging 
at the time of diagnosis for HCC patients.  Due to numbers, patients without cirrhosis 
were treated as having Child-Pugh A disease.  The Charlson Comorbidity Index (CCI) 





- Unknown treatment 
(n=7)









via a combination of International Classification of Diseases 9th Edition codes as well as 
HBsAg and HCV Ab laboratory data and included both treated and untreated patients as 
well as those currently in treatment and those who had achieved sustained virologic 
response.  Patients with missing viral hepatitis data (n=4 in HCC, n=49 in ICC) were 
considered as “non-viral” hepatitis. 
 
Baseline inflammatory markers, namely the NLR (NLR=neutrophils/lymphocytes), 
platelet-to-lymphocyte ratio (PLR=platelets/lymphocytes), and systemic immune-
inflammatory index (SII=neutrophils*lymphocytes/platelets), were calculated using lab 
values drawn within 30 days prior to treatment.   
 
Statistical Analysis 
Pre-treatment immune biomarkers (NLR, PLR, and SII) were dichotomized at the median 
for visualization purposes.  For all other survival analyses, biomarkers were log-
transformed and evaluated as linear predictors.  Categorical variables were compared 
using the 2 test and continuous variables using the Wilcoxon rank sum test.  Kaplan-
Meier methods and log-rank tests were used to estimate overall survival.  When survival 
curves crossed, the Wilcoxon test was employed in order to account for early survival 
losses.  The Cox proportional hazards method was used to identify predictors of overall 
survival (OS).  Non-normally distributed continuous variables were log-transformed for 
survival modelling.  Patient, liver, and tumor factors that were significant (p<0.05) on 







An alpha-level of <0.05 was considered statistically significant, and all P-values reported 
are two-sided.  Calculations were performed using JMP Pro v.13.0.0 (SAS Institute Inc., 
Cary, NC); R version 3.4.3 (R Core Development Team, Vienna, Austria); and RStudio 
version 1.1.414 (RStudio Inc., Boston, MA).  Additional figures were created using 
GraphPad Prism version 7.0a for Mac (GraphPad Software, La Jolla, CA).   
 
Contribution of Authors 
All data collection and organization as well as the vast majority of statistical analysis was 
conducted by Cortlandt M. Sellers.  Hyun S. Kim contributed to study design.  Statistical 
optimization of biomarkers was first performed by Johannes Uhlig and then repeated and 




The hepatocellular carcinoma arm of this study consisted of 581 patients who met 
inclusion criteria (see Fig. 5a), including 455 (78.3%) men and 126 (21.7%) women, with 
an overall mean age of 62.110.0 years. 385 patients (66.2%) were Caucasian.  The 
etiologies underlying liver disease and HCC were HCV infection (333 patients, 57.3%), 
HBV infection (21 patients, 3.6%), combined HBV/HCV infection (17 patients, 2.9%), 
alcohol (65 patients, 11.2%), and nonalcoholic steatohepatitis (50 patients, 8.6%). For 





hundred and eleven patients (70.7%) had a histopathologically proven diagnosis of HCC; 
the other 170 (29.3%) had a radiologic diagnosis only.   
 
The most frequent treatment received was transarterial chemoembolization (n=155, 
26.7%), and the majority of patients had Child-Pugh A disease (n=351, 60.4%), while 
163 patients (28.1%) had Child-Pugh B disease, and 57 patients (9.8%) had Child-Pugh C 
disease.  Seventy patients received systemic therapy (12.0%), of whom 63 (90%) 
received sorafenib, and 7 (10%) received other systemic agents, including regorafenib, 
gemcitabine, cisplatin, adriamycin, doxorubicin, atelizumab, and/or bevacizumab.  
Additional baseline demographic and tumor variables are provided in Tables 1 and 2.  
Mean follow-up time was 33.4 months (SD=30.7 mo) and 333 patients (57.3%) died 
during the study period.  
 
ICC Demographics 
One hundred and nine patients with intrahepatic cholangiocarcinoma met inclusion 
criteria, with a mean follow-up time of 20.0 months (SD=18.1 mo).  Eighty-seven 
patients (79.8%) died during the study period (see Fig. 5b for study design).  The annual 
incidence of ICC diagnosis increased over time, from 2 patients diagnosed in 2005 to 14 
patients in 2016, with a maximum of 25 cases in 2014.  
 
Mean age among ICC patients was 63.0 years (SD=10.5 yrs), and the population was 
50.4% male (n=55) and 78.9% Caucasian (n=86). 78.9% of patients (n=86) were non-





Eleven patients presented with AJCC Stage I disease (10.1%); 25 had Stage II disease 
(22.9%); 11 had Stage III disease (10.1%); and 43 patients had Stage IV disease (39.4%).  
At diagnosis, 57 patients (52.3%) had multifocal intrahepatic cholangiocarcinoma, 48 
patients (44.0%) had bilobar cholangiocarcinoma, 27 patients had vascular invasion 
(24.8%), and 46 patients (42.2%) had metastatic disease.  Median tumor size at the time 
of diagnosis was 6.4 cm (IQR 4.1-8.5).  Refer to Table 3 for further baseline patient and 
tumor factors. 
 
Among ICC patients, four received thermal ablation (3.7%), 65 patients received 
systemic therapy (59.6%), 12 patients had TACE or Y90 (11.0%), and 28 patients 
underwent resection (25.7%).  Treatment subgroups were then further divided into three 
groups: patients who received resection or locoregional therapies (LRT) with or without 
subsequent systemic therapy (Group 1, n=35, 32.1%); patients who received systemic 
therapy followed by LRT or resection (Group 2, n=9, 8.3%); and patients who received 
systemic therapy alone (Group 3, n=65, 59.6%). 
 
Intrahepatic cholangiocarcinoma patients who received surgery had fewer comorbidities 
as measured by the Charlson Comorbidity Index (CCI) than patients who had non-
surgical treatment (surgical median CCI 5.0 vs. non-surgical median CC 7.0, p=0.0003).  
In addition, the surgical group had slightly lower median MELD scores (6.0) vs. the non-
surgical group (7.0, p=0.0379).  Surgical patients also had smaller median tumor size (4.2 





disease, and lower rates of extrahepatic metastases (p>0.05).  Patients with advanced 
AJCC stage disease were less likely to receive surgical treatment (p=0.0006). 
 
Overall Survival of the cohort 
The median overall survival time for the hepatocellular carcinoma cohort was 34.9 
months, with 1-, 3-, and 5- year survival rates of 75.2%, 48.7%, and 34.9% respectively.  
Transplant patients had the highest survival rates, with median OS not reached and 5-year 
OS of 86.2%, followed by resection (median OS 51.1 mo), ablation (36.5 mo), combo 
LRT (27.9 mo), transarterial chemoembolization (22.2 mo) and systemic therapy (5.1 
mo; overall p<0.0001).  Fig. 6 demonstrates the Kaplan-Meier cumulative OS curves of 
patients stratified according to therapy.  
 
Time 
(months) 0 6 12 24 48 72 96 120 144 
Combined 
 (# at risk)  581 511 420 291 140 75 46 14 2 
Transplant 99 99 99 88 71 46 28 10 2 
Resection 98 87 78 60 28 13 8 4 0 
Ablation 90 84 67 44 12 6 4 0 0 
Combo 
LRT 74 69 58 38 12 4 4 0 0 




























TACE 155 141 102 57 17 6 2 0 0 
Systemic 
Therapy 70 31 16 4 0 0 0 0 0 
 
Fig. 6. Overall Survival of HCC patients by treatment allocation  
 
Median overall survival for the intrahepatic cholangiocarcinoma cohort was 16.5 months 
(IQR: 12.9-19.6), with 1-, 3-, and 5-year survival rates of 63.7%, 22.8%, and 12.7% 
respectively.  Among patients who had documented clearance of their 
cholangiocarcinoma (n=27, 24.8%), the confirmed recurrence rate was 51.9% (n=14) vs. 
no recurrence (n=13, 48.1%).  There were no significant differences across patient, liver, 
and tumor characteristics between patients who had recurrence of their ICC and those 
who did not.  
 
When stratified by treatment approach, survival among ICC patients was highest in 
resection (median OS 43.8 mo, 95% CI: 29.2-62.5 mo), followed by locoregional 
therapies (median OS 33.1 mo, 95% CI: 5.6 mo-not reached), systemic therapy (median 
OS 11.0 mo, 95% CI: 8.4-13.4 mo, overall p<0.0001).  There was a trend towards 
improved survival in patients who received locoregional therapies treatment with/without 
systemic therapy vs. patients who received systemic therapies alone (p=0.0627).  On 
multivariable analysis, locoregional therapy demonstrated a survival benefit vs. systemic 
therapy (HR 3.98, 95% CI: 1.485-12.660, p=0.0047 ). 
 
 Overall survival was highest in Group 1 (39.3 mo), followed by Group 2 (median OS 
33.1 mo), then Group 3 (11.0 mo, p<0.0001) (Fig. 7a).  In ICC patients with Child-Pugh 





36.4 mo vs. 54.6 mo vs. 13.3 mo, p<0.0001) (Fig. 7b).  In patients with Child-Pugh class 
B disease, there was a non-significant trend towards improved survival for patients in 
Group 1 vs. Group 3 (median OS 24.7 mo vs. 7.1 mo, p=0.2175) (Fig. 7c).  
a)  
Months Since 
Diagnosis 0 6 12 24 48 72 96 
Combined (# at 
risk) 109 87 68 36 10 4 0 
Systemic Therapy, 
then 
Resection/LRT 9 9 9 5 2 0 0 
Resection/LRT first 35 30 28 23 8 4 0 
Systemic Therapy 
only 65 48 31 8 0 0 0 
 
b)  
















l Resection/LRT First - Child-Pugh A 
Systemic, then Resection/LRT - Child-Pugh A


















Fig. 7. Overall survival in ICC by treatment group. a) entire cohort; b) Child-Pugh A 
patients; c) Child-Pugh B patients 
 
Prognostic Factors for Overall Survival 
As shown in Table 4, univariate significant predictors associated with decreased survival 
(p<0.05) included older age, increased comorbidities, non-viral hepatitis, higher Child-
Pugh score, advanced BCLC stage, advanced AJCC stage, increased tumor size, 
multifocal tumors, bilobar tumor burden, vascular invasion, and extrahepatic metastases 
as well as increased log-transformed alpha-fetoprotein.  On multivariable analysis, 
















l Resection/LRT First - Child-Pugh B 
Systemic, then Resection/LRT - Child-Pugh B
Systemic Only - Child-Pugh B
p=0.2175
Months Since 
Diagnosis 0 6 12 24 48 72 96 
Combined (# at risk) 86 69 61 32 8 2 0 
Systemic Therapy, 
then Resection/LRT 8 8 8 5 2 0 0 
Resection/LRT first 29 24 23 19 6 2 0 
Systemic Therapy 
only 49 37 30 8 0 0 0 
Months Since 
Diagnosis 0 6 12 24 48 72 96 
Combined (# at risk) 14 11 4 3 2 2 0 
Systemic Therapy, 
then Resection/LRT 0 0 0 0 0 0 0 
Resection/LRT first 4 4 4 3 2 2 0 
Systemic Therapy 





decreased survival was associated with Child-Pugh B disease, BCLC stage D disease, 
AJCC stage IV disease, bilobar tumor burden, non-viral hepatitis and log-transformed 
alpha-fetoprotein (AFP) (p<0.05) (See Table 5). 
 
Among patients with intrahepatic cholangiocarcinoma, factors significant on univariate 
analysis included Charlson comorbidities index, MELD score, AJCC staging, MELD, 
tumor size, tumor location, presence of multifocal disease, extrahepatic metastases, and 
treatment allocation (Table 6).  Factors that were not significant on univariate Cox 
analyses included age, gender, race, Child-Pugh score, viral hepatitis status, and vascular 
invasion.  Significant factors (p<0.05) on MVA included treatment allocation (Table 7). 
 
Immune Biomarkers in HCC 
Overall, the HCC cohort had a median platelet count of 117.5*10^3/L (IQR 77.0-
196.0), with median absolute neutrophil count (ANC) of 3.2*10^3/L (IQR 2.2-4.4) and 
median absolute lymphocyte count of 1.3*10^3/L (IQR (0.83-1.8).  On univariate Cox 
models, increased neutrophils were associated with decreased survival (HR 1.17, 95% CI: 
1.11-1.22, p<0.0001), as were increased platelets (HR 1.003, 95% CI: 1.002-1.004, 
p<0.001).  Absolute lymphocyte count did not significantly affect patient survival on 
univariate analyses.  After stratifying neutrophils at the median, higher rates of increased 
neutrophil count were seen in patients who were older, male, white, had increased 
comorbidities, non-viral hepatitis, lower MELD scores, advanced BCLC staging, 
advanced AJCC staging, larger tumor size, had bilobar tumors, and patients who received 






The median NLR was 2.45 (neutrophils/lymphocytes), median PLR was 96.28 
(platelets/lymphocytes), and median SII was 290.05 (neutrophils*platelets/lymphocytes).  
As depicted in Fig. 8, there was good to very strong correlation between the 
inflammatory markers (PLR and NLR, Spearman =0.62; SII and NLR, =0.74; SII and 
PLR, =0.85). 
a)  b)  
c)  
Fig. 8. Correlation between log-transformed inflammatory biomarkers among HCC 
patients. a) NLR and PLR. b) NLR and SII. c) PLR and SII 
 
Decreased NLR, PLR and SII were each associated with increased survival after 
dichotomization (median OS for above versus below median: log-transformed NLR 45.6 
vs. 23.9 months, p<0.001; log-transformed PLR 44.1 vs. 24.9 months, p<0.001; log-
transformed SII 44.1 vs. 24.2 months, p<0.001).These findings proved independent from 





1.34, 95% CI: 1.10-1.63, p=0.0033; log-transformed PLR: HR 1.32, 95% CI 1.07-1.64, 
p=0.0101; log-transformed SII HR 1.17, 95% CI 1.01-1.37, p=0.0415).  However, when 
including all three biomarkers in one multivariable analysis, only the neutrophil-to-
lymphocyte ratio remained significant.  Therefore, the remainder of our analyses were 
conducted using the NLR as the sole biomarker. 
 
Patients in the low-NLR group were more likely to be African American (16.9%) or 
Hispanic (17.2%) than patients in the high-NLR group (8.9% and 15.1%, respectively, 
p=0.0048). Decreased NLR was associated with lower comorbidity indices vs. the 
increased NLR group (median CCI 6 vs. 7, p<0.0001); higher rates of viral hepatitis 
(73.8% vs. 52.9%, p<0.0001); higher percentage of Child-Pugh A disease (71.1% vs. 
51.9%, p<0.0001), lower MELD score (low-NLR median 8.5 vs. high NLR median 10, 
p<0.0001); less advanced BCLC Staging; lower rates of AJCC Stage III/IV disease 
(16.3% vs. 28.4%, p=0.0079); higher rates of unilobar tumors; and lower median tumor 
size (2.8 cm vs. 3.2 cm, p=0.0003).  
 
Patients in the low-NLR group had lower rates of ethanol-related (7.6%) or NASH-
related HCC (7.2%) versus patients in the high-NLR group (14.8% and 10.0% 
respectively, overall p<0.0001).  Patients in the low-NLR group were more likely to 
receive ablation (17.9%), combo LRT (15.5%), and resection (19.7%) than patients in the 
high-NLR group (13.1%, 10.0%, and 12.4% respectively) and less likely to receive 
systemic therapy (6.6% vs. 17.5%), transarterial chemoembolization (25.5% vs. 27.8%) 





diagnosis of HCC, there was no significant association between tumor differentiation and 
neutrophil count, lymphocyte count, or NLR. 
a)  
Time (months) 0 6 12 24 48 72 96 120 144 
Combined  
(# at risk) 
581 509 415 287 137 72 43 14 2 
NLR<median (# 
at risk) 
290 270 236 171 78 38 23 8 2 
NLR>=median (# 
at risk) 
291 239 179 116 59 34 20 6 0 
b)  
Time (months) 0 6 12 24 48 72 96 120 144 
Combined  
(# at risk) 
210 172 142 98 48 30 17 4 0 
NLR<median (# 
at risk) 
75 71 66 51 28 15 6 2 0 
NLR>=median (# 
at risk) 
135 101 76 47 20 15 11 2 0 



















































Fig. 9. Survival curves in HCC by NLR group and viral hepatitis. a) entire cohort. b) non-
viral hepatitis. c) Viral hepatitis 
 
Log-transformed NLR was associated with decreased OS after multivariable adjustment 
for confounders (HR=1.34, 95% CI: 1.102-1.628, p=0.0033).  The impact of the NLR 
was then tested across treatment subgroups.  As shown in Fig. 9a, the low-NLR group 
(<median NLR=2.455) demonstrated higher median OS of 45.6 mo vs. the high-NLR 
group (median OS 23.9 mo, p<0.0001).  Notably, the effect of the NLR was strongest in 
systemic therapy (low vs. high NLR: median OS 12.3 mo vs. 4.1 mo, p=0.0008); TACE 
(low vs. high NLR: median OS 31.5 mo vs. 16.4 mo, p=0.0018); and resection (low vs. 
high NLR: median OS 62.4 mo vs. 42.8 mo, p=0.0357).  While a survival disadvantage 
was also seen in the low NLR group for ablation (low vs. high NLR: median OS 37.1 mo 
vs. 35.2 mo, p=0.2901), combo LRT (low vs. high NLR: median OS 32.6 mo vs. 19.1 




















Time (months) 0 6 12 24 48 72 96 120 144 
Combined  
(# at risk) 
371 339 276 191 91 44 28 10 1 
NLR<median (# 
at risk) 
215 200 172 121 51 24 18 5 1 
NLR>=median (# 
at risk) 





mo, p=0.0873), and transplant (low vs. high NLR: median OS not reached; 5-year OS 
92.3% vs. 81.5%, p=0.1061), these did not reach statistical significance. 
 
Severity of Liver Disease and Neutrophil-to-Lymphocyte Ratio 
There was no significant difference in the distribution of neutrophils across Child-Pugh 
classes; however, decreased lymphocytes were seen with increased Child-Pugh class.  
Patients with Child-Pugh class A disease had the highest median absolute lymphocyte 
count (1.4, IQR 1.1-1.94), followed by patients with class B disease (median 1.0, IQR 
0.7-1.5), and patients with class C disease (median 0.97, IQR 0.64-1.4, overall 
p<0.0001).  Median platelet count decreased as the severity of liver disease increased 
(Class A median 136.5 [IQR 92.8-214.0], class B 99.0 [IQR 65.0-151.0], class C 73.0 
[IQR 51.0-111.0], p<0.0001).  Median NLR increased with worsening liver disease 
(Child-Pugh A 2.2 [1.6-3.3] , Child-Pugh B 3.2 [1.8-4.5], Child-Pugh C 3.6 [2.3-5.5], 
p<0.0001).  Median PLR and median SII were similar across Child-Pugh groups.  
 
In patients with mild liver disease (Child-Pugh class A), the low-NLR group again 
demonstrated improved survival (median OS 54.0 mo) vs. the high-NLR group (29.3 mo, 
p<0.0001).  Similar results were seen in the Child-Pugh B group (low-NLR vs. high-
NLR, median OS 26.4 mo vs. 13.6 mo, p=0.0035).  However, the neutrophil-to-
lymphocyte ratio appeared to be less significant in patients with advanced Child-Pugh 
Class C liver disease (low-NLR group vs. high-NLR group, median OS 22.3 mo vs. 66.4 
mo, p=0.3338).  The interaction term between NLR group and Child Pugh class was not 





(n=23) received liver transplantation, as compared to 20.9% of patients with Child-Pugh 
class B disease (n=34), and 11.7% of patients with class A disease (n=41) (overall 
p<0.01).  
 
Viral hepatitis (chronic inflammation) and Neutrophil-to-Lymphocyte Ratio 
Hepatocellular carcinoma patients with viral hepatitis had higher survival from diagnosis 
of HCC (median OS 38.9 mo) vs. non-viral hepatitis patients (27.7 mo, p=0.0286).  
Patients with viral hepatitis were more likely to be male and African American than 
patients with non-viral hepatitis (p<0.05) and had lower comorbidities indices, lower 
AJCC staging, higher median AFP, decreased median tumor size, and decreased 
frequency of bilobar tumors (p<0.05) (See Table 2).  
 
Hepatocellular carcinoma patients without viral hepatitis had higher rates of systemic 
therapy, resection, and TACE and lower rates of ablation, combo LRT, and transplant 
(p<0.01).  While patients with viral hepatitis had higher rates of BCLC stage 0 or A 
disease and lower rates of BCLC stage B disease compared to patients with non-viral 
hepatitis, rates of BCLC stage C and D disease were similar between the two groups.  
HCC patients with and without viral hepatitis were similarly distributed in terms of 
Child-Pugh score, MELD score, presence of multifocal tumors, vascular invasion, and 
extrahepatic metastases. 
 
HCC patients without viral hepatitis vs. those with viral hepatitis had higher absolute 





counts (median 149*10^3/L vs. 110*10^3/L, p<0.0001).  Absolute lymphocyte counts 
were similar between the two groups (median 1.3*10^3/L vs. 1.3*10^3/L, p=0.0502). 
The median NLR was higher in non-viral hepatitis patients (median NLR=3.0) vs. viral 
hepatitis patients (median NLR=2.2, p<0.0001), as was the median PLR (123.3 vs. 78.2, 
p<0.0001) and the median SII (445.9 vs. 237.7, p<0.0001).  
 
On multivariable Cox survival analyses, viral hepatitis was identified as an effect 
modifier for NLR: the interaction term between hepatitis status and log-transformed NLR 
was significant on MVA (p=0.0274).  As depicted in Fig. 9b, in non-viral hepatitis 
patients NLR below versus above the median was associated with increased survival 
(median OS 56.7 vs. 17.6 mo, p<0.0001).  However, in the presence of viral hepatitis, the 
prognostic relevance was attenuated (Fig. 9c, low vs. high NLR: median OS 41.8 vs. 35.2 
mo, Wilcoxon: p=0.0109).  Similar findings were observed for a chronic infection group 
including all viral hepatitis and human immunodeficiency virus (HIV) patients. 
 
Inflammatory Markers in Intrahepatic Cholangiocarcinoma 
Inflammatory Marker Selection 
One-hundred and nine ICC patients had laboratory blood work within the 30-day period.  
Median absolute neutrophil count for the cohort was 5.2*10^3/L (IQR 3.5-7.2), with 
median absolute lymphocyte count of 1.4*10^3/L (IQR 1.0-1.9), and median platelets 
of 227*10^3/L (IQR 162-318.5).  Decreased absolute neutrophil count and increased 
absolute lymphocyte count were associated with a survival benefit on univariate analyses 





not affect survival on either UVA or MVA.  The median NLR for the cohort was 3.5 
(IQR 2.3-6.0) and the median PLR was 153.3 (IQR 111.4-219.3) and a median SII of 
865.9 (455.0-1333.0).  Correlation between inflammatory markers ranged from good 
(PLR and NLR, Spearman =0.69) to very strong (PLR and SII, =081; NLR and SII, 
p=0.84) (see Fig. 10). 
 
a) b)   
 
c)    
Fig. 10. Correlation between log-transformed inflammatory biomarkers among ICC 
patients. a) NLR and PLR. b) NLR and SII. c) PLR and SII 
 
Decreased NLR was associated with increased survival (p<0.01) (see Fig. 11a), as was 
the SII, while dichotomized PLR was not (p=0.3). On MVA, log-transformed NLR 
remained an independent prognostic factor (HR 1.81, p<0.05).  Neither PLR nor SII were 
































































independent prognostic factors on MVA (p>0.05), and thus the NLR was used in all 
further subgroup analyses. 
 
Neutrophil-to-Lymphocyte Ratio  
ICC patients with an NLR greater than the median had larger median tumor size (7.3 cm 
vs. 5.6 cm, p=0.0023) and were younger and had lower rates of viral hepatitis.  Patients 
across NLR groups were similar in terms of age, gender, race/ethnicity, cirrhosis status, 
Child-Pugh score, MELD score, AJCC stage, multifocal disease, vascular invasion, 
tumor location, and presence of extrahepatic metastases (p>0.5).  Patients in the low NLR 
group had improved median OS (NLR<=3.5, 23.2 mo, IQR 16.8-32.5 mo) vs. patients in 
the high NLR group (NLR>3.5, median OS 12.4 mo, IQR 6.2-14.2 mo).  When stratified 
into treatment subgroups, the NLR remained a significant factor in patients treated with 
systemic therapy (NLR<=3.96 vs. NLR >3.96; median OS 13.4 mo vs. 9.5 mo, p=0.018). 
A trend towards improved survival was also seen in the resection (n=28; NLR<=median 
vs. NLR >median; median OS 43.8 mo vs. 39.3 mo, p=0.55) and locoregional therapy 



























































Diagnosis 0 6 12 24 48 72 96 
Combined (# at risk) 59 87 67 35 10 5 0 
NLR<=median 56 51 40 24 8 3 0 
NLR>median 3 36 27 11 2 2 0 
Months Since 
Diagnosis 0 6 12 24 48 72 96 
Combined (# 
at risk) 86 70 60 31 7 2 0 
NLR<=median 43 40 34 21 7 2 0 







Diagnosis 0 6 12 24 48 72 96 
Combined (# 
at risk) 14 11 5 4 2 2 0 
NLR<=median 7 6 3 2 0 0 0 
NLR>median 7 5 2 2 2 2 0 
 
Fig. 11. Overall survival by neutrophil-to-lymphocyte ratio and Child-Pugh status in ICC 
patients.  a) entire cohort b) Child-Pugh A patients. c) Child-Pugh B patients. 
 
Liver status and neutrophil-to-lymphocyte ratio 
Patients were further stratified by Child-Pugh score. Due to low numbers (n=1), the 
patient with Child-Pugh C disease was excluded.  Those with Child Pugh B disease had 
more comorbidities as measured by the CCI (10.0) vs. patients with Child Pugh A disease 
(6.0, p<0.0001), as well as higher median MELD scores (9.5 vs. 7.0, p=0.0192), and 
higher rates of cirrhosis and multifocal ICC (p<0.05).  Both Child Pugh groups were 
similar in terms of age, gender, race/ethnicity, viral hepatitis, cirrhosis AJCC staging, 
tumor size, vascular invasion, treatment allocation, and inflammatory biomarkers.  
 
In Child-Pugh class A (n=86), low NLR had higher OS vs. high NLR (29.2 mo vs. 12.2 
mo, p=0.0007) (see Fig. 11b).  In Child-Pugh class B (n=14), NLR did not have a 
























significant effect on median OS (low vs. high NLR: 8.3 mo vs. 6.2 mo, p=0.6) (see Fig. 
11c).  Child-Pugh class was further identified as an effect modifier on MVA for log-
transformed NLR (p=0.0029).  
 
When stratifying the ICC cohort by viral hepatitis, the NLR continued to be an effective 
marker of survival both in non-viral hepatitis (n=90) (low-NLR vs. high-NLR; median 
OS 21.8 vs. 13.0 mo, p=0.0270) and in viral hepatitis (n=19) (low-NLR vs. high-NLR; 
median OS 29.2 mo vs. 3.8 mo, p=0.0030).  Further, the interaction term between log-
transformed NLR and viral hepatitis status was nonsignificant on MVA. 
 
Discussion 
According to 2018 data from the International Agency for Research on Cancer, primary 
liver cancer is the seventh most common cancer worldwide (1) and the third most 
common cause of cancer death (2).  Estimations from Surveillance, Epidemiology, and 
End Results Program (SEER), a governmental database complied in the United States, 
concluded that there were 35,600 newly diagnosed cases of PLCs in the U.S. in 2015, 
with an estimated 24,500 deaths (67).  An estimated 70-85% of primary liver cancers are 
due to hepatocellular carcinoma, and as many as 60% of HCC cases globally arise from 
HBV or HCV infection (1, 10, 68).  While hepatitis B is the predominant viral hepatitis 
strain in Asia, hepatitis C is more common in the United States.  Several biomarkers have 
been postulated as prognostic and predictive makers for HCC, but evidence on their role 






Intrahepatic cholangiocarcinoma is the second most common form of primary liver 
cancers (69) and has a very poor prognosis.  In our cohort,  HCC made up approximately 
84% of primary liver cancer cases, and ICC comprised roughly 13% of cases.    
 
During the study period, the annual number of HCC cases increased from 13 in 2005 to 
62 in 2016, and the annual number of ICC cases diagnosed at our institution increased 
from 2 in 2005 to 14 in 2016.  It has been noted globally that the incidence of ICC has 
been rising over the past few decades (26).  Examinations of SEER data have 
demonstrated both increased incidence as well as increased mortality over a twenty-year 
period from 1973 to 1997 (70).  Another study of the SEER database during a similar 
time period found that incidence had increased by 165% (71).  While the SEER data 
demonstrated that the 1-year survival rate increased significantly (from 15.8% during the 
first 5 years of the study to 26.3% during the final five years), the five-year survival rate 
did not change (2.6% vs. 3.5%).  In our cohort, we did not see significant differences in 
survival of our ICC patients over time.  Although ICC continues to remain a rare liver 
malignancy, this increased number of annual cases is concerning and makes the need for 
improved types of treatment even more critical.  
 
Locoregional therapies and Unresectable ICC 
On multivariable analyses, locoregional therapies demonstrated a survival advantage 
compared to systemic therapy alone in patients with unresectable ICC.  Multiple forms of 
locoregional treatment have been examined in ICC.  It is thought that both TACE (33) 





TACE has also been used successfully as adjuvant therapy alongside chemotherapy (35) 
and surgical resection (36).  Upon comparing resection with TACE, Sheuermann et al 
(72) found that there was no survival benefit for resection vs. TACE in patients with 
positive lymph nodes or positive resection margins after surgery.  A meta-analysis 
reviewing various forms of LRT treatments delivered through the hepatic artery 
concluded that direct chemotherapeutic infusion through the hepatic artery had improved 
survival versus TACE, drug-eluting bead TACE, and Y-90 (37).  Radiofrequency 
ablation has also been shown to prolong survival in inoperable ICC, particularly in 
tumors measuring less than 5 cm (38, 73).   
 
Collectively, this evidence suggests that locoregional therapies may be a good are of 
continued discovery for future treatment of ICC, particularly in patients whose 
comorbidities prevent them from being surgical candidates or who are unable to tolerate 
the significant side effects of systemic chemotherapy. 
 
NLR in HCC 
For several solid tumors including HCC, an increased neutrophil-to-lymphocyte has been 
described as a biomarker associated with decreased overall survival (49, 50, 51, 52, 53, 
54).  The NLR has been examined in HCC following transplant (74, 75) resection (76, 
77), radiofrequency ablation (78, 79, 80), TACE (81, 82, 83), radioembolization (84), and 
sorafenib (85, 86, 87).  However, while the utility of the NLR has been reported in HBV-
related HCC, few studies have analyzed the effect of the NLR in an HCC population with 





conducted in European or Asian populations and their results might not be generalizable 
to the more diverse US population.  An exception was Sullivan et. al, who utilized 
regression models to analyze the predictive value of the NLR in a Western (US) 
population of HCC and did not find the NLR to be a significant predictor of survival (89).  
Somewhat similarly, Zheng et al examined the impact of six inflammatory markers 
including the NLR and PLR on recurrence-free survival (RFS) and OS in HCC in a 
Western cohort and found only the PLR to be independently associated with RFS and OS 
(90). 
 
Upon assessing the prognostic impact of NLR, PLR, and SII in HCC, NLR emerged as 
the single most relevant biomarker and was independently associated with decreased 
overall survival.  This effect carried through in our subgroup analyses to patients treated 
with systemic therapy, TACE, and resection.  Although high-NLR patients in the 
combined LRT, ablation, and transplant subgroups showed a trend toward decreased 
survival with increasing NLR, results did not reach statistical significance, which could 
be attributable to smaller sample sizes.  
 
NLR, liver disease, and chronic viral hepatitis in HCC. 
The effects of the neutrophil-to-lymphocyte ratio varied with advanced liver disease and 
the presence of viral hepatitis. In patients with Child-Pugh class A or B disease, the 
neutrophil-to-lymphocyte ratio stratified above and below the median was a significant 
prognostic factor for HCC patients, even within Child Pugh scores.  However, a high 





Pugh class C).  Similarly, Wang and colleagues (91) reviewed a cohort of HBV-HCC 
patients and observed that high NLR or high PLR was not associated with poorer survival 
in patients with cirrhosis (Ishak stage 6) and was only associated with poorer survival in 
patients with early-to-moderate stage fibrosis (Ishak stages 0-5).  It should be noted that 
while in our cohort non-cirrhotics were combined with Child-Pugh A patients due to low 
numbers, the Child-Pugh measurement is generally only calculated for patients with 
cirrhosis and designates increasing liver dysfunction in the context of cirrhosis itself. 
 
In the case of chronic viral hepatitis, while the viral hepatitis and non-viral hepatitis 
cohorts were different in terms of BCLC staging, AJCC staging, comorbidities index, 
median AFP, mean tumor size, rates of bilobar tumors, and treatment allocation, the 
interaction term between log-transformed NLR and hepatitis status was significant on 
MVA adjusting for those factors as well as multiple other patient, liver status, and tumor 
variables.  The NLR was less impactful in patients with viral hepatitis than patients 
without viral hepatitis.  This may in part be due to the effects of chronic inflammation.  
Our findings further demonstrated that HCC patients with chronic viral hepatitis had 
lower neutrophil and platelet counts than patients without hepatitis.  Viral hepatitis 
patients also had a lower median NLR than patients without hepatitis.  
 
Although decreased NLR in our study was associated with fewer co-morbidities (possibly 
due to decreased systemic disease burden and decreased systemic inflammation), higher 
rates of viral hepatitis, less advanced liver disease, less advanced cancer staging, and 





survival on multivariable analysis.  This suggests that the mechanism of action of NLR 
may not be through severity of liver disease or stage of HCC but through other 
mechanisms.  
 
Inflammation and intrahepatic cholangiocarcinoma 
Cholangiocarcinomas are thought to arise from increased proliferation of the 
cholangiocytes that make up the biliary epithelium (92, 93), and ICC in particular is a 
very heterogenous tumor.  Besides the three distinct gross forms of ICC, there are also 
multiple morphologies on the cellular (94) and molecular (95) levels.  Risk factors such 
as primary sclerosis cholangitis and intrahepatic lithiasis cause cellular injury, which 
activates the inflammatory response, leading to increased cholangiocyte proliferation as 
well as the production of free radicals and multiple other cytokines and growth and 
angiogenic factors, thus continuing the cycle of injury and proliferation (40, 42) and 
creating an ideal cellular environment for carcinogenesis (41, 96).  This is a similar 
pathway to that which has been described in HCC following exposure to hepatitis b virus 
in a transgenic mouse model (97), where prolonged injury leads to inflammation, 
regenerative hyperplasia, transcriptional deregulation, and aneuploidy before the eventual 
development of neoplasia.    
 
 Inflammatory Markers in ICC 
We observed strong correlation among the neutrophil-to-lymphocyte ratio, platelet-to-
lymphocyte ratio, and systemic immune-inflammatory index.  Upon further analysis, 





multivariable proportional hazards analyses.  Likewise, Ha and colleagues (98) studied 
the NLR, PLR, and SII as well as soluble programmed cell death ligand-1 in 158 patients 
with advanced biliary tract cancers, including ICC, gallbladder carcinoma, extrahepatic 
cholangiocarcinoma, and tumors of the ampulla of Vater.  They concluded that only NLR 
and soluble PD-L1 were independent prognostic factors.  As the study of circulating 
inflammatory biomarkers continues, it will be important to determine the relative 
predictive vs. prognostic values of the neutrophil-to-lymphocyte ratio and other 
commonly studied biomarkers. 
 
Neutrophil-to-lymphocyte ratio in ICC 
In this cohort, a neutrophil-to-lymphocyte ratio greater than the median was associated 
with decreased survival. This survival difference was also seen on subgroup analyses in 
among patients who received systemic therapy, and there was a trend towards improved 
survival with decreased NLR in the surgery and LRT treatment groups.  While this trend 
was non-significant, this may have been due to the small numbers in the surgery and LRT 
subgroups.  
 
As a marker of that increased inflammation in patients with intrahepatic 
cholangiocarcinoma, an increased neutrophil-to-lymphocyte ratio has been associated 
with poor prognosis following surgery (62, 65, 99) and chemotherapy (63, 65).  It has 
been a component of potential prognostic systems (100) as well as nomograms for the 
prediction of resection futility (101).  A recent meta-analysis that comprised 26 studies 





primary liver cancers, subgroup analyses suggested that the predictive role of NLR in 
cholangiocarcinomas might be limited (102).  Of note, only 29 of these 4,461 patients 
had confirmed ICC.   
 
Neutrophil-to-lymphocyte ratio and liver status 
Child-Pugh status was demonstrated to be an effect modifier of the NLR in our cohort.  It 
should be noted, however, that the Child-Pugh A and Child-Pugh B groups in our cohort 
had similar distribution of inflammatory markers.  This suggests that there is more at play 
beyond the degree of cirrhosis being correlated with the degree of inflammation.  
Perhaps, in cases of significant or advanced chronic inflammation, the immune system 
becomes fatigued, and the rates of increased neutrophils may be fewer.  In light of the 
low numbers of Child-Pugh class B patients present in this cohort, there may be smaller 
effects and nuances that are being missed due to low-power.  
 
Immune Mechanisms 
The interplay between cancer formation and the immune system is complex. Neutrophils 
have been found to have both pro-tumor and anti-tumor properties (103).  Chronic 
inflammation, such as that which occurs in the setting of chronic hepatitis B and hepatitis 
C infection, has been associated with increased susceptibility for the development of 
cancers (104).  Bolte et. al found decreased intra-hepatic mucosal-associated invariant T 
cells in patients with chronic HCV as compared to controls (105).  These chronic 
infections affect the immune system by creating a constant cycle of inflammation, 





well as the production of reactive oxygen species and resultant DNA damage (104, 106, 
107). 
 
Although our study focused solely on circulating markers of inflammation, it is plausible 
that the NLR may be associated with changes in the tumor microenvironment.  There is 
no consensus about how the NLR affects the immunologic composition of HCC.  For 
example, Sun concluded that high levels of intratumoral regulatory T-cells (T-regs) were 
associated with poor survival in HCC, while high levels of peritumoral T-regs were not 
(108).  On meta-analysis, Zhang and colleagues reported that both increased peripheral 
blood T-regs and increased intratumoral T-regs were associated with poorer survival 
(109).  
 
Wang et al. reviewed NLR and tumor-infiltrating lymphocytes (TILs) in laryngeal 
squamous cell carcinoma.  Although they found that both high NLR and low TILs were 
significantly correlated with decreased OS and recurrence-free survival (RFS), no 
correlation between either NLR and TILs or PLR and TILs was evident (110).  Other 
studies have found the NLR to be related to higher levels of intratumoral neutrophils in 
HCC (111).  While there is less published work on the NLR in intrahepatic 
cholangiocarcinoma,  Lin et al (64) examined 102 patients with ICC and saw that higher 
PD-1+CD4+ and PD-1+CD8+ T cells were found in the high NLR group while higher 
amounts of IFN+CD4+ and IFN+CD8+ T cells were seen in the low NLR group.  
Further, the high NLR group experienced an increased density of tumor-infiltrating CD3+ 






The strengths of the NLR over PLR and SII as seen in this study and others (98) suggest 
that it may be the neutrophil component which so strongly drives the effect of the NLR, 
and not the lymphocytic component.  By releasing further inflammatory cytokines, 
neutrophils may increase the rates of cellular injury and continue to propagate an 
intercellular and intra-tumoral environment that is ideal for carcinogenesis.  Neutrophils 
may also be one of the leading carriers of peripheral vascular endothelial growth factor 
(VEGF) in patients with cancer.  Kusumanto et al. (112) found that cancer patients 
carried an increased percentage of total circulating VEGF in granulocytes, including 
neutrophils (69%) vs. healthy volunteers (58%).  Further, oncologic patients had a 
decreased percentage of circulating VEGF in their platelets as compared to controls. 
Given the vast heterogeneity of intrahepatic cholangiocarcinomas and hepatocellular 
carcinomas at the cellular level, further work is required to establish the precise 
relationship between systemic inflammatory markers and local inflammation in HCC and 
its microenvironment.  In addition, as platelet count is highly linked to progression of 
portal hypertension in cirrhotics, the PLR may be less applicable in HCC than in other-
non-cirrhotic cancers studied to date. 
  
NLR and Systemic Therapy 
Of the treatments visualized in subgroup analyses, the NLR had the strongest effect in 
systemic chemotherapy HCC patients, with survival in the low-NLR group being almost 
three times as high as survival in the high-NLR group.  The majority of these patients 





may be prudent to stratify analyses by viral or non-viral HCC, particularly since subgroup 
analyses of the SHARP trial demonstrated significant benefit in HCV patients (113), who 
would likely have a lower NLR.  In addition, it may be possible to utilize the NLR as a 
means of determining which patients would benefit most from systemic chemotherapy 
among the non-viral HCC population.  
 
This strong survival difference was also seen in intrahepatic cholangiocarcinoma patients 
treated with systemic therapy.  In light of the poorer survival experienced by patients 
treated with systemic therapy in the high-NLR group, primary liver cancer patients with a 
high neutrophil-to-lymphocyte ratio and unresectable disease might benefit more from 




Our study included a diverse, well-characterized cohort regarding age, gender, race, and 
ethnicity as well as diverse treatment modalities.  Our sample size is a limiting factor in 
subgroup analyses; however, our HCC cohort is among the largest studies in which NLR 
has been examined.  While this study relied on archived records, we limited the NLR 
values to within thirty days of HCC or ICC treatment in order to improve standardization.  
This study was conducted among a Western (U.S.) population, and results may differ in 






Conclusions: After comparing the neutrophil-to-lymphocyte ratio, platelet-to-
lymphocyte ratio, and systemic immune-inflammation index, it appears that the 
neutrophil-to-lymphocyte ratio has the strongest impact as a prognostic marker in 
intrahepatic cholangiocarcinoma and hepatocellular carcinoma.  This increased survival 
is modulated by liver status and chronic viral hepatitis, suggesting that the interplay 
between intracellular inflammation and liver parenchymal dysfunction may further affect 
survival.  The greatest survival difference between low- and high- neutrophil-to-
lymphocyte groups was seen in patients treated with systemic chemotherapy.  Additional 
work is needed to further clarify the predictive value of the NLR and how changes in 
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platelet-lymphocyte-ratio (PLR) <0.01 
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(62.5 - 142.8) 
132.7 




systemic immune-inflammatory index (SII) <0.01 











Treatment < 0.01 
  Resection 93 (16.0%) 36 (12.4%) 57 (19.7%)  
  Ablation 90 (15.5%) 38 (13.1%) 52 (17.9%)  
  Systemic Therapy 70 (12.0%) 51 (17.5%) 19 (6.6%)  
  Combo LRT 74 (12.7%) 29 (10.0%) 45 (15.5%)  





  Transplant 99 (17.0%) 56 (19.2%) 43 (14.8%)  
Male Gender 455 (78.3%) 219 (75.5%) 236 (81.1%) 0.10 
Age 
61.0 (56.0 - 
68.0) 
62.0 (57.0 - 
70.0) 




  Black, Non-
Hispanic 
75 (12.9%) 26 (8.9%) 49 (16.9%)  
  Hispanic 94 (16.2%) 44 (15.1%) 50 (17.2%)  
  Other/Unknown 27 (4.7%) 10 (3.4%) 17 (5.9%)  
  White, Non-
Hispanic 




6.0 (5.0 - 8.0) 7.0 (6.0 - 8.0) 6.0 (5.0 - 7.0) <0.01 
Viral Hepatitis < 0.01 
  Viral hepatitis 371 (63.9%) 156 (53.6%) 215 (74.1%)  
  None 210 (36.1%) 135 (46.4%) 75 (25.9%)  
etiology of HCC <0.01 
HCV  333 (57.3%) 135 (46.4%) 198 (68.3%)  
HBV 21 (3.6%) 8 (2.8%) 13 (4.5%)  
HBV/HCV 17 (2.9%) 13 (4.5%) 4 (1.4%)  
Ethanol 65 (11.2%) 43 (14.8%) 22 (7.6%)  





Other 95 (16.4%) 63 (21.7%) 32 (11.0%)  
Child Pugh score < 0.01 
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AJCC stage <0.01 
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Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile 
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT – 
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV – 
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of End-
stage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; 
AJCC – American Joint Committee on Cancer staging system.  
Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile 
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT – 
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV – 
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of End-
stage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; 
AJCC – American Joint Committee on Cancer staging system.  
  
  Unilobar 411 (70.7%) 192 (66.0%) 219 (75.5%)  
  Bilobar 162 (27.9%) 91 (31.3%) 71 (24.5%)  
Vascular Invasion 95 (16.4%) 60 (20.6%) 35 (12.1%) 0.02 
Extrahepatic 
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61.0 (56.0 - 
68.0) 
59.0 (55.0 – 
64.0) 




  Black, Non-
Hispanic 
75 (12.9%) 65 (17.5%) 10 (4.8%)  
  Hispanic 94 (16.2%) 60 (16.2%) 34 (16.2%)  
  Other/Unknown 27 (4.7%) 23 (6.2%) 4 (1.9%)  
  White, Non-
Hispanic 




6.0 (5.0 - 8.0) 6.0 (5.0 - 7.0) 7.0 (6.0-9.0) <0.01 
Viral Hepatitis < 0.01 
  Viral hepatitis 371 (63.9%) 371 (100%) 0 (0.0%)  
  None 210 (36.1%) 0 (0.0%) 210 (100.0%)  
etiology of HCC <0.01 
   HCV  333 (57.3%) 333 (89.8%) 0 (0.0%)  
  HBV 21 (3.6%) 21 (5.7%) 0 (0.0%)  
  HBV/HCV 17 (2.9%) 17 (4.6%) 0 (0.0%)  
  Ethanol 65 (11.2%) 0 (0.0%) 65 (31.0%)  





  Other 95 (16.4%) 0 (0.0%) 95 (45.2%)  
Child Pugh score 0.81 
  A 351 (60.4%) 221 (59.6%) 130 (61.9%)  
  B 163 (28.1%) 106 (28.6%) 57 (27.1%)  
  C 57 (9.8%) 38 (10.2%) 19 (9.0%)  
MELD score 
9.0 (7.0 - 
13.0) 
9.0 (7.0 – 
13.0) 
10.0 (7.0 – 
13.0) 
0.11 
BCLC score 0.01 
  0 or A 132 (22.7%) 95 (25.6%) 37 (17.6%)  
  B 84 (14.5%) 42 (11.3%) 42 (20.0%)  
  C 268 (46.1%) 173 (46.6%) 95 (45.2%)    
  D 67 (11.5%) 43 (11.6%) 24 (11.4%)  
AJCC stage 0.04 
  1 266 (45.8%) 173 (46.6%) 93 (44.3%)  
  2 162 (27.9%) 114 (30.7%) 48 (22.9%)  
  3 80 (13.8%) 42 (11.3%) 38 (18.1%)  
  4 43 (7.4%) 25 (6.7%) 18 (8.6%)  
Tumor size <0.01 
  Median (IQR) 2.9 (2.0 - 4.8) 2.7 (2.0 – 4.4) 
3.5 (2.4 – 
6.3) 
 
Multifocal HCC 0.26 
  Yes 233 (40.1%) 155 (41.8%) 78 (37.1%)  





Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile 
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT – 
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV – 
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of End-
stage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; AJCC – American Joint Committee 






HCC location 0.04 
  Unilobar 411 (70.7%) 265 (71.4%) 146 (69.5%)  
  Bilobar 162 (27.9%) 103 (27.8%) 59 (28.1%)  
Vascular Invasion 95 (16.4%) 56 (15.1%) 39 (18.6%) 0.31 
Extrahepatic 
Metastases 























   Caucasian, non-
Hispanic 86 (18.9%) 44 (83.0%) 42 (75.0%) 
 
   Black, Non-
Hispanic 10 (9.2%) 5 (9.4%) 5 (8.9%) 
 
   Hispanic 8 (7.3%) 1 (1.9%) 7 (12.5%) 
 
  Other/Unknown 5 (4.6%) 3 (5.7%) 2 (3.6%)  
Charlson 
Comorbidities Index 7.0 (5.0-9.0) 7.0 (5.0-10.0) 6.5 (4.3-8.0) 0.1644 
Viral Hepatitis 19 (17.4%) 5 (9.4%) 14 (25.0%) 0.0292 




   A 86 (78.9%) 43 (81.1%) 43 (76.8%) 
 
   B  14 (12.8%) 7 (13.2%) 7 (12.5%) 
 
   C  1 (0.9%) 1 (1.9%) 0 (0.0%) 
 
MELD Score 7.0 (6.0-9.0) 7.0 (6.0-10.0) 7.0 (6.0-8.3) 0.3681 
AJCC Stage 






   I 11 (10.1%) 2 (3.8%) 9 (16.1%) 
 
   II 25 (22.9%) 11 (20.8%) 14 (25.0%) 
 
   III 11 (10.1%) 6 (11.3%) 5 (8.9%) 
 
   IV 43 (39.4%) 22 (41.5%) 21 (37.5%) 
 




   Unilobar 61 (56.0%) 26 49.1%) 35 (62.5%) 
 
   Bilobar 48 (44.0%) 27 (50.9%) 21 (37.5%) 
 
 Vascular Invasion 27 (24.8%) 15 (28.3%) 12 (21.4%) 0.4059 
Multifocal Disease 57 (52.3%) 28 (52.8%) 29 (51.8%) 0.9131 
Metastatic Disease 46 (42.2%) 23 (43.4%) 23 (41.1%) 0.5045 




















   Resection 28 (25.7%) 10 (18.9%) 18 (32.1%) 
 
   LRT 16 (14.7%) 8 (15.1%) 8 (14.3%) 
 
   Systemic Therapy 65 (59.6%) 35 (66.0%) 30 (53.6%) 
 
Data presented as median (IQR) or N (%). Abbreviations: NLR – neutrophil-to-lymphocyte ratio; MELD – 
Model for End-stage Liver Disease; AJCC – American Joint Committee on Cancer; PLR – platelet-to-












Age 1.02 1.01 1.03 <0.01 
Female Gender (male as reference) 0.79 0.60 1.02 0.08 
Race/ethnicity 
  Caucasian (reference) 
  African American 
1.27 0.92 1.72 0.15 
  Hispanic 1.05 0.77 1.40 0.74 
  Other/Unknown 0.64 0.33 1.11 0.12 
Comorbidities (continuous) 1.17 1.12 1.23 <0. 01 
Hepatitis (vs. none) 0.78 0.63 0.98 0.03 
MELD score (continuous) 1.00 0.98 1.01 0.59 
Child-Pugh Class 
   
  A (reference) 
   
  B 1.73 1.36 2.18 <0.01 
  C 1.05 0.70 1.51 0.81 
BCLC Stage     
  0 or A (reference)     
  B 2.55 1.72 3.81 <0.01 
  C 2.38 1.72 3.37 <0.01 
  D 2.16 1.40 3.32 <0.01 
AJCC  
    
  1 
   





Abbreviations used: HCC – hepatocellular carcinoma; HR – hazard ratio; CI – confidence interval; MELD 
– Model of End-stage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; AJCC – American 
Joint Committee on Cancer staging system; TACE – transarterial chemoembolization; LRT – locoregional 
  3 3.44 2.53 4.63 <0.01 
  4 6.25 4.27 8.95 <0.01 
Tumor size (continuous) 1.08 1.06 1.11 <0.01 
Tumor Number 
   
  Solitary (reference) 
   
  Multiple/Multifocal 1.67 1.35 2.07 <0.01 
Tumor Location 
   
  Unilobar (reference) 
   
  Bilobar 2.24 1.79 2.81 <0.01 
Vascular Invasion 4.31 2.85 6.63 <0.01 
Metastatic Disease 4.77 3.48 6.44 <0.01 
Treatment 
    
  Resection (reference) 
   
  Transplant 0.22 0.12 0.38 <0.01 
  Ablation 1.79 1.18 2.73 <0.01 
  TACE 2.69 1.86 3.89 <0.01 
  Combo LRT 2.36 1.57 3.55 <0.01 
  Chemo 13.73 9.06 20.79 <0.01 
log(AFP) 1.22 1.18 1.27 <0.01 
log(NLR) 1.47 1.25 1.73 <0.01 
log(PLR) 1.78 1.48 2.14 <0.01 





therapy; AFP – alpha-fetoprotein; NLR – neutrophil-to-lymphocyte ratio; PLR- platelet-to-lymphocyte 








Table 5. Prognostic factors in HCC on multivariable analysis 
Predictor HR lower.95.CI upper.95.CI Pval 
log(NLR) 1.34 1.10 1.63 <0.01 
log(AFP) 1.08 1.02 1.14 <0.01 
Viral Hepatitis 0.67 0.50 0.90 <0.01 
Child-Pugh Class 
   
  A (reference) 
   
  B 2.18 1.54 3.07 <0.01 
  C   0.37 0.15 0.98 <0.05 
BCLC Stage     
  0 or A 
(reference) 
    
  B 1.57 0.96 2.58 0.08 
  C 1.37 0.91 2.07 0.13 
  D 5.67 2.54 12.65 <0.01 
AJCC Stage 
    
  1 (reference) 
   
  2 1.29 0.91 1.82 0.15 
  3 1.82 1.18 2.82 <0.01 
  4 2.18 1.24 3.80 <0.01 
Tumor location 
   
  Unilobar (reference) 
   







    
  Resection 
(reference) 
    
  Transplant 0.14 0.07 0.28 <0.01 
  Ablation 1.26 0.66 2.42 0.49 
  Combo LRT 2.11 1.12 3.97 0.02 
  TACE 1.54 0.88 2.69 0.13 
  Systemic 
therapy 
4.49 2.31 8.74 <0.01 
Interaction term: Log(NLR)*Viral Hepatitis 0.0274 
 Abbreviations used: HCC – hepatocellular carcinoma; HR – hazard ratio;  
CI – confidence interval; NLR – neutrophil-to-lymphocyte ratio;  



























Table 6: Significant Prognostic Markers on Univariate Analysis in ICC patients 
Factor 
 
HR Lower 95% Upper 95% P-value 
Charlson comorbidity    
  Index 
1.23 1.127 1.340 <0.0001 
MELD 1.06 1.024 1.099 0.0028 
AJCC stage  
    
   I (reference) 
   
   II  2.37 0.976 6.624 0.0569 
   III  3.29 1.110 10.375 0.0319 
   IV  6.96 2.932 19.644 <0.0001 
Tumor size 1.11 1.036 1.179 0.0031 
Tumor location 
   
   Unilobar (reference) 
   
   Bilobar 2.01 1.286 3.127 0.0024 
Multifocal Tumor 2.21 1.427 3.447 0.0004 
Metastases 2.85 1.804 4.506 <0.0001 
Treatment  
  
   Resection (reference) 
   
   LRT 1.87 0.746 4.361 0.1728 
   Systemic 6.85 3.686 13.656 <0.0001 
log(NLR) 1.93 1.366 2.698 0.0002 
log(PLR) 1.52 1.024 2.275 0.0374 





Abbreviations: MELD – Model for End-stage Liver Disease; AJCC – American Joint Committee on 
Cancer; LRT – locoregional therapies; NLR – neutrophil-to-lymphocyte ratio; PLR – platelet-to-





Table 7: Significant Prognostic Markers on Multivariate Analysis in ICC patients 
Factor HR Lower 
95% 
Upper 95% P-value 
Treatment Allocation  
 
   Resection (reference) 
   
   LRT 1.24 0.388 3.674 0.7070 
   Systemic 4.92 1.977 13.036 0.0005 
Log(NLR) 1.81 1.137 2.867 0.0125 
Interaction term: Log(NLR)*Child-Pugh score 0.0029 
Abbreviations: HR – hazard ratio; LRT – locoregional therapies; NLR – neutrophil-to-lymphocyte ratio 
